| Published June 17, 2025

Eli Lilly acquires Verve Therapeutics for $1,3 billion

Eli Lilly has signed an agreement to acquire Verve Therapeutics for up to $1,3 billion, sending Verve's stock up 75 percent in premarket trading on Tuesday. The deal includes an initial payment of $10,50 per share and up to $3 per share in contingent payments tied to clinical milestones for VERVE-102, a Phase Ib gene therapy for cardiovascular diseases. The transaction is expected to close in Q3 2025.